Kratom Lobby Helped Loosen Limits on a Potent Opioid Compound as Deaths Climbed

health

A billion-dollar kratom industry spent millions on lobbying and political giving while the federal government reversed course and allowed twenty times more of the opioid compound 7-OH in products sold at gas stations nationwide.

Kratom, derived from a Southeast Asian tree, acts on the same opioid receptors as oxycodone, heroin and fentanyl, and it sits on shelves in tens of thousands of stores and online. The CDC detected kratom in more than 5,000 overdose deaths between 2020 and 2024, and toxicologist Justin Brower of NMS Labs says kratom-linked fatalities have risen roughly tenfold since 2014, with dozens of deaths attributed to kratom alone.

Four families described sons who took kratom for energy or to ease off alcohol. Two of the men died with mitragynine, kratom's main opioid, as the sole cause; the other two died from mixtures that included mitragynine alongside prescription or over-the-counter drugs.

The government announced in July that it would restrict 7-OH and three related substances. Last month, the Department of Health and Human Services changed that recommendation, raising the permitted 7-OH level twentyfold, a move that left former FDA commissioner Marty Makary and former senior HHS advisor Calley Means stunned. HHS said neither political contributions nor outside pressure influenced the decision, and the American Kratom Association says natural kratom differs from chemically manipulated products. The FDA still warns consumers not to use kratom at all, citing liver toxicity, seizures and substance use disorder.